Hepatitis B Virus Clinical Trial
Official title:
Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Safety, and Tolerability of Escalating Single Dose & Multiple Dose by Using Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitits B Patients
The purpose of this study is to evaluate the dosages of recombinant human serum albumin/interferon alpha2b fusion protein injection on HBV subjects. The secondary purposes is to get the PK/PD data in recombinant human serum albumin/interferon alpha2b fusion protein injection on HBV subjects.
This is an open-label study that will be conducted at three sites in China to characterize the PK/PD profile, safety and tolerability of Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein in HBV subjects. Subjects will receive a single dose of Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein or active comparator Pegasys at Day 0. A multipule-dose administration in HBV subjects will last 12 weeks after four weeks washout period. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03459521 -
Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease.
|
N/A | |
Completed |
NCT02060162 -
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
|
||
Completed |
NCT00912847 -
Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma
|
N/A | |
Completed |
NCT04072211 -
Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District
|
Phase 4 | |
Completed |
NCT01204762 -
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
|
Phase 2 | |
Completed |
NCT00805675 -
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
|
Phase 3 | |
Completed |
NCT02785835 -
Hepatocellular Carcinoma in HIV-infected Patients
|
||
Completed |
NCT03083821 -
A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting
|
Phase 1 | |
Recruiting |
NCT01083251 -
The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection
|
N/A | |
Not yet recruiting |
NCT05752890 -
A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma
|
||
Recruiting |
NCT04231565 -
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
|
N/A | |
Terminated |
NCT00678587 -
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
|
Phase 3 | |
Completed |
NCT00739752 -
Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics
|
N/A | |
Withdrawn |
NCT04385524 -
Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection
|
N/A | |
Enrolling by invitation |
NCT00663182 -
Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
|
Phase 4 | |
Completed |
NCT00769730 -
Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication
|
N/A | |
Completed |
NCT01438424 -
Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
|
Phase 2 | |
Withdrawn |
NCT04046107 -
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
|
Phase 1/Phase 2 | |
Completed |
NCT05406089 -
Effects of Antiviral Therapy on Patients With HBV-related HCC
|
||
Completed |
NCT03625258 -
Mutations of the Pre-core Region of Hepatite B Virus (HBV)
|